SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 25.04+2.6%Nov 21 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bradpalm1 who wrote (3621)6/20/1998 10:53:00 PM
From: Ibexx  Read Replies (1) of 9523
 
Brad,

The non-approvable letter on Zeldox is not enough of an excuse for a major sell-off, the street is more sophisticated than that.

First of all, "non-approvable" simply means "non-approvable based upon the data contained in the NDA; it is by no means "the final verdict".

Secondly, the Street (the major brokerages anyway) had thus far only factored in a modest revenue stream from Zeldox sales for the upcoming years. A slight change in timeframe will in no way impact materially on PFE's N/T and I/T earnings, period. (Just to cite an example, H&Q's analysis factored in 500 million of worldwide revnues for Zeldox five years down the road.)

I would be extremely surprised if there is a significant sell-off on Monday. If it does happen, I would be as happy as a lark to scoop up LEAPS options.

Ibexx
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext